Zobrazeno 1 - 10
of 277
pro vyhledávání: '"Gilbert J. Burckart"'
Autor:
Gelareh A. Abulwerdi, Anuradha Ramamoorthy, Edward Bashaw, Gilbert J. Burckart, Rajanikanth Madabushi, Elimika Pfuma Fletcher
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 10, Pp 2046-2057 (2023)
Abstract Deriving pediatric doses for locally acting drugs (LADs) presents a unique challenge because limited systemic exposure hinders commonly used approaches such as pharmacokinetic matching to adults. This study systematically evaluated drug deve
Externí odkaz:
https://doaj.org/article/27577306551548d5bd65d5511cbee4ed
Autor:
Sherbet Samuels, Jayabharathi Vaidyanathan, Elimika Pfuma Fletcher, Anuradha Ramamoorthy, Rajanikanth Madabushi, Gilbert J. Burckart
Publikováno v:
Children, Vol 10, Iss 10, p 1640 (2023)
Clinical trials are an integral aspect of drug development. Tremendous progress has been made in ensuring drug products are effective and safe for use in the intended pediatric population, but there remains a paucity of information to guide drug dosa
Externí odkaz:
https://doaj.org/article/87ee388fef464f18a3a6c44bedc89cc3
Autor:
Xiaomei I. Liu, Dionna J. Green, John N. van den Anker, Natella Y. Rakhmanina, Homa K. Ahmadzia, Jeremiah D. Momper, Kyunghun Park, Gilbert J. Burckart, André Dallmann
Publikováno v:
Frontiers in Pediatrics, Vol 9 (2021)
Background: While physiologically based pharmacokinetic (PBPK) models generally predict pharmacokinetics in pregnant women successfully, the confidence in predicting fetal pharmacokinetics is limited because many parameters affecting placental drug t
Externí odkaz:
https://doaj.org/article/f4541b75f8c84cbd94df9dab5d82a079
Publikováno v:
Frontiers in Pediatrics, Vol 9 (2021)
The regulatory framework for considering the fetal effects of new drugs is limited. This is partially due to the fact that pediatric regulations (21 CFR subpart D) do not apply to the fetus, and only US Health and Human Service (HHS) regulations appl
Externí odkaz:
https://doaj.org/article/a64124a612a143cabac0ab7f15975980
Autor:
Peng Duan, Fang Wu, Jason N. Moore, Jeffrey Fisher, Victor Crentsil, Daniel Gonzalez, Lei Zhang, Gilbert J. Burckart, Jian Wang
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 3, Pp 158-166 (2019)
The objective of this study was to develop pediatric physiologically based pharmacokinetic (PBPK) models for pantoprazole and esomeprazole. Pediatric PBPK models were developed by Simcyp version 15 by incorporating cytochrome P450 (CYP)2C19 maturatio
Externí odkaz:
https://doaj.org/article/4046c6703a334b57aba320be38d56c4d
Autor:
John N. Van den Anker, Susan McCune, Pieter Annaert, Gerri R. Baer, Yeruk Mulugeta, Ramy Abdelrahman, Kunyi Wu, Kevin M. Krudys, Jeffrey Fisher, William Slikker, Connie Chen, Gilbert J. Burckart, Karel Allegaert
Publikováno v:
Pharmaceutics, Vol 12, Iss 7, p 685 (2020)
Drug dosing in neonates should be based on integrated knowledge concerning the disease to be treated, the physiological characteristics of the neonate, and the pharmacokinetics (PK) and pharmacodynamics (PD) of a given drug. It is critically importan
Externí odkaz:
https://doaj.org/article/82e74c75cfd048299f83e88632c4f44d
Publikováno v:
The Journal of Clinical Pharmacology.
Publikováno v:
The Journal of Clinical Pharmacology.
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:957-959
The Research to Accelerate Cures and Equity (RACE) for Children Act requires an assessment of molecular targets relevant to pediatric cancer. Due to the biological complexity, candidate molecular targets have been primarily evaluated based on single
Autor:
Jerry H. Gurwitz, Bindu Kanapuru, Rajanikanth Madabushi, Jamie Gamerman, Francesca Cerreta, Jack Cook, Robert M. Califf, Paul Goldsmith, Daphne Guinn, Sharon K. Inouye, Robert Temple, Janice B. Schwartz, Piet H. van der Graaf, Carolyn R. Cho, Munir Pirmohamed, Barbara Radziszewska, Patricia W. Slattum, Qi Liu, Sarah N. Hilmer, Shiew-Mei Huang, H. Keipp Talbot, Phil Posner, Gilbert J. Burckart, S.W. Johnny Lau, Sebastian Haertter
Publikováno v:
Clinical pharmacology and therapeutics, vol 112, iss 2
CLINICAL PHARMACOLOGY & THERAPEUTICS
CLINICAL PHARMACOLOGY & THERAPEUTICS
Changes that accompany older age can alter the pharmacokinetics (PK), pharmacodynamics (PD), and likelihood of adverse effects (AEs) of a drug. However, older adults, especially the oldest or those with multiple chronic health conditions, polypharmac